RxDoctor Payments Data

Paula Macmorran

Knoxville, TNNPI 1710989215

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.1% of the total across 224 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 19.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $2,696 and has fallen 83.0% since, to $459 in 2024.

$5,496in general payments, 2019–2025

Across 224 payments — averaging $24.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Supernus Pharmaceuticals, Inc.$1K
  • AbbVie$950
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$943
  • Otsuka America Pharmaceutical, Inc.$449
  • Teva Pharmaceuticals USA, Inc.$335
  • Adlon Therapeutics L.p.$202
  • plus $2K from 12 others

What the payments were for

  • Food & beverage$5,44999%
  • Education$471%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Where these figures come from

Is this you, or does something look wrong? →